Spectrum Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview

Spectrum Pharmaceuticals

13/03/2023 20:13

* Spectrum Pharmaceuticals Inc  SPPI.OQ   SPPI.O  is
expected
to show a rise in quarterly revenue when it reports  results on
March 15 (estimated). 
    * The Henderson Nevada-based  company is expected to report
revenue of $8.92 million, according to the mean estimate from 5
analysts, based on Refinitiv data.  The company's guidance on
January 31 2023, for the period ended December 31, was for
revenue of $10.000 million.
    * ​Refinitiv's mean analyst estimate for Spectrum
Pharmaceuticals
Inc is for a loss of 11 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Spectrum
Pharmaceuticals Inc is $3.5​, above​ its last closing price
of $0.79. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.15       -0.15      -0.12     Beat    18.6
 Jun. 30 2022  -0.15       -0.16      -0.17     Missed  -7.6
 Mar. 31 2022  -0.20       -0.19      -0.08     Beat    58.3​
 Dec. 31 2021              -0.21      -0.26     Missed  -21.5
 ​​Sep.        -0.28       -0.28      -0.21     Beat    25
 30 2021                                                
 Jun. 30 2021  -0.25       -0.25      -0.32     Missed  -25.5​
 Mar. 31 2021  -0.30       -0.31      -0.25     Beat    20.6
 Dec. 31 2020              -0.29      -0.29     Met     0
 This summary was machine generated March 13 at 20:13 GMT.  All
figures in US dollars  unless otherwise stated